CliffBio
small molecule

AMYVID

FLORBETAPIR F-18

Loss of exclusivityApril 2027latest FDA-listed patent expiry
CompanyAvid Radiopharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMYVID
Active ingredientFLORBETAPIR F-18
Strength10-30ML (13.5-51mCi/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalApril 2012
Marketing statusDISCN

Listed patents

PatentExpiresType
7687052April 2027substance, product
8506929April 2027substance, product

More from Avid Radiopharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AMYVID patent cliff — loss of exclusivity April 2027 | CliffBio